Background {#Sec1}
==========

The incidence of melanoma is increasing rapidly worldwide, including countries with historically low rates. This increase is occurring at a faster rate than with any other neoplasm \[[@CR1]\]. Up to one-fifth of melanoma patients develop metastatic disease, which has mainly been treated by chemotherapy, achieving response rates between 10 and 30% \[[@CR2]\]. After cancers of the lung and breast, melanoma is the third most common cause of central nervous system (CNS) metastases \[[@CR3], [@CR4]\]. In patients with newly diagnosed stage IV disease, brain metastases are present in 20% of cases \[[@CR5]\] and among patients with documented brain involvement, these lesions contribute to death in up to 95% \[[@CR6]\]. In 40--60% of all melanoma patients, mutational activation of BRAF V600E can be found, resulting in constitutive activation of the serine-threonine protein kinase BRAF and the Ras-RAF-MEK-ERK signaling pathway, also known as mitogen activated protein (MAP) kinase pathway \[[@CR7]\]. Until 2011, standard treatment for patients with inoperable metastatic melanoma was dacarbazine (DTIC) \[[@CR8]\]. In August 2011, the US Agency of Food and Drug Administration (FDA) approved Vemurafenib, a BRAF inhibitor (BRAFi), for the treatment of metastatic or unresectable melanoma with BRAF V600E mutation. Brain metastases pose special challenges because of the poor associated prognosis \[[@CR9]\]. They are a major cause of mortality in patients with advanced melanoma. However, relatively little was known about the intracranial effectiveness of selective inhibitors because patients with brain metastases have historically been excluded from clinical trials \[[@CR10]\]. Recently a few studies investigated BRAFi treatment for melanoma patients with brain metastasis \[[@CR11]--[@CR13]\]. An open-label pilot study assessed Vemurafenib therapy in patients with BRAF V600 mutation positive metastatic melanoma with non-resectable, previously treated brain metastases and concluded that Vemurafenib can safely be used for the therapy of advanced symptomatic melanoma with metastasis to the brain and can result in meaningful tumor regression \[[@CR11]\]. In more than 50% of these cases clinical response, up to a complete remission, were achieved by Vemurafenib. Systemic therapy revolutionized melanoma treatment but unfortunately high initial responses are followed by acquired drug resistance after a median time of only 6--8 months \[[@CR14], [@CR15]\]. About 15% of the patients treated with BRAFi do not achieve tumor regression, because of intrinsic (primary) mechanisms of resistance and most patients who respond to therapy ultimately develop mechanisms of acquired (secondary) resistance, leading to progressive disease \[[@CR16]\]. Initial success was made by BRAFi therapy, but due to the reactivation of the MAPK signaling pathway, patients showed resistance to therapy. Therefore a combination therapy of BRAF and MEK inhibitors (MEKi) was implemented and improved the effectiveness of targeted therapy even further by improving median PFS \[[@CR17], [@CR18]\]. Unfortunately, resistance to therapy is still challenging and especially the high mortality of brain metastases poses a huge ongoing clinical problem. It is questionable whether there are brain specific efflux transporters contributing to the resistance of intracranial metastases and where differences or similarities between visceral and cerebral metastases can be found. The phenotype-switching model was first described in melanoma by Hoek et al. \[[@CR19], [@CR20]\] and characterizes two transcriptional distinct melanoma cell populations, a proliferative and an invasive type. Melanoma cells are able to switch back and forth between these two phenotypes and therefore explain the heterogeneous nature of melanoma cells \[[@CR21]\]. It accounts for disease progression and tumor heterogeneity, as well as aspects of resistance \[[@CR22]\]. Proliferative melanoma cells have been shown to be more responsive to MAPK pathway inhibition than invasive phenotype cells, independently of their mutation status \[[@CR23], [@CR24]\]. On the other hand, proliferative melanoma cells have shown to change their phenotype from proliferative to invasive state in response to long-term treatment with targeted therapy (BRAFi and MEKi), which is associated with drug resistance. The major role in phenotype switching and the transition from a proliferative to an invasive cell type and ultimately leading to metastasis is played by EMT-like mechanisms \[[@CR25]\]. Identifying critical switches in EMT processes and finding a way to block these, might serve as a strategy to prevent metastasis and to decrease therapeutic resistance. Especially, the down-regulation of E-cadherin, balanced by the increased expression of mesenchymal neural cadherin (N-cadherin), this, so called cadherin switch, alters cell adhesion \[[@CR26], [@CR27]\] and is considered to be a fundamental event in EMT, leading to a loss of cell--cell contact, increased invasive properties and typical morphological changes \[[@CR21], [@CR28], [@CR29]\].

In this study we showed, by analyzing brain tissue samples of patients with low and high PFS in response to MAPKi treatment, distinct differences between the two groups, using proteome profiling by shotgun MS. We analyzed the data according to gene ontology (GO) terms, KEGG pathways and gene set enrichment analysis (GSEA). We were further able to identify an EMT mechanism (up-regulation of N-cadherin), V-type proton ATPases, calcium ion binding proteins, eukaryotic translation initiation factors, cell adhesion proteins, several transporter and exchanger proteins in poor responding patients, whereas good responders showed an immune activation and involvement of extracellular matrix structural constituents, among other features. Based on nearest shrunken centroids we furthermore detected the most discriminating proteins between those two groups. We validated the EMT like signature using primary melanoma cells derived from cerebral metastases with different response based on the IC50 to BRAF and MEK inhibitors. To validate the discriminative signature we used the CPL/MUW proteome database \[[@CR30]\]. By a subsequent targeted approach, we performed a quantification and validation step of this discriminative signature. Functional analysis of the EMT signature was performed by inducing EMT in a primary melanoma cell culture. As a final step we validated our findings clinically by correlating our protein signature with survival over TCGA analysis and immunohistochemical staining (for study design see Additional file [1](#MOESM1){ref-type="media"}: Fig. S1).

Methods {#Sec2}
=======

All experiments were carried out according to the Declaration of Helsinki principles after approval by the ethics committee (Swissethics, Kantonale Ethikkommission Zurich, vote number 2014-0425). Cerebral melanoma metastases (n = 25) originating from surgical excisions and autopsy specimens were selected based on the clinical information and patients' different progression-free survival (PFS) after MAPKi treatment. For subsequent data analysis patients with a PFS ≥ 6 months were classified as a good responder (n = 9) and showed low progression, whereas patients with a PFS ≤ 3 months were classified as a poor responder (n = 16) and showed fast progression in their disease. Further validation steps included melanoma cells derived from cerebral metastases (n = 5) and FFPE (formalin-fixed paraffin-embedded) cerebral melanoma metastases tissue samples (n = 23), corresponding to patients from the initial metastases cohort. A clinical table with age, gender, treatment, response distribution, PFS, mutational status, all number of samples, IC50 of the cell systems and the applied methods can be found as Additional file [2](#MOESM2){ref-type="media"}: Table S1.

LC--MS sample preparation {#Sec3}
-------------------------

2--5 mg of each cryopreserved tissue sample and cell pellets from confluent 75 cm^2^ tissue culture flasks were homogenized in 100 μl sample buffer (7.5 M Urea, 1.5 M Thiourea, 0.1 M dithiothreitol (DTT), 4% 3-\[(3-Cholamidopropyl)dimethylammonio\]-1-propanesulfonate (CHAPS), 0.05% Sodium dodecyl sulfate (SDS)) using ultrasound. Protein concentrations were determined according to Bradford et al. \[[@CR31]\]. For proteome analysis we prepared in-solution digests using a variation of the FASP protocol \[[@CR32]\], as previously described \[[@CR33]\]. Of each lysate 20 µg protein was concentrated onto a 10 kDa MWCO filter (molecular weight cut-off filter; Pall Nanosep Centrifugal Devices with Omega Membrane, \#OD010), which was prewashed with LC--MS grade water (Merck Chemicals and Life Science GesmbH, Vienna, Austria), by centrifugation at 14,000×*g* for 15 min to remove all particles smaller than 10 kDa. Samples containing proteins were then reduced with 200 µl dithiothreitol (DTT) solution (5 mg/ml dissolved in 8 M guanidinium hydrochloride in 50 mM ammonium bicarbonate buffer, pH 8) and incubated at 56 °C for 30 min. After centrifugation at 14,000×*g* for 10 min, a washing step with 50 mM ammonium bicarbonate buffer was performed. For alkylation 200 µl iodoacetamide (IAA) solution (10 mg/ml in 8 M guanidinium hydrochloride in 50 mM ammonium bicarbonate buffer) was added and incubated at 30 °C for 30 min in the dark. After centrifugation at 14,000×*g* for 10 min, proteins on top of the filters were washed with 50 mM ammonium bicarbonate buffer. Afterwards, filters were placed in a new Eppendorf tube, and 100 µl of 50 mM ammonium bicarbonate buffer as well as 10 µl of protease solution (Promega Trypsin/Lys-C Mix, Mass Spec Grade, \#V5073, 0.1 µg/µl) were added, and incubated at 37 °C for 18 h. After digestion, peptide samples were cleaned up with C-18 spin columns (Thermo Fisher Scientific Pierce C18 spin columns, \#89870). Peptides were collected with 0.5% trifluoroacetic acid (TFA) and acidified to a final concentration of 1% TFA. C-18 columns were prewashed two times with 500 µl acetonitrile (ACN) and equilibrated with 200 µl of 5% ACN and 0.5% TFA by centrifugation at 1500×*g* for 1 min. Eluted and acidified peptide samples were loaded onto prewashed and equilibrated spin columns. After centrifugation at 1500×*g* for 1 min, the flow-through was reloaded on the column to maximize peptide binding and again centrifuged. After a washing step with 5% ACN and 0.5% TFA, peptides were eluted twice with 40 µl 50% ACN and 0.1% TFA and once with 40 µl 80% ACN and 0.1% TFA into a new Eppendorf tube. Digested peptide samples were finally dried at 40 °C using a centrifugal vacuum concentrator (miVac GeneVac Duo Concentrator) and stored at − 20 °C until further MS analyses were performed.

LC--MS/MS shotgun analysis {#Sec4}
--------------------------

As described previously \[[@CR33], [@CR34]\], dried samples were reconstituted in 5 µl 30% formic acid (FA) containing 10 fmol each of 4 synthetic standard peptides (allowing us to monitor the quality of the chromatographic separation) and diluted with 40 µl mobile phase A (98% H~2~O, 2% ACN, 0.1% FA). Of this solution 2.5 µl were injected into the Dionex Ultimate 3000 nano HPLC-system (Thermo Fisher Scientific). Peptides were first concentrated on a 2 cm × 75 µm C18 Pepmap100 pre-column (Thermo Fisher Scientific) at a flow rate of 10 µl/min using mobile phase A. Afterwards, separation of the peptides was achieved by eluting them from the pre-column to a 50 cm × 75 µm Pepap100 analytical column (Thermo Fisher Scientific) applying a flow rate of 300 nl/min and using a gradient of 8% to 40% mobile phase B (80% ACN, 20% H~2~O, 0.1% FA), over 190 min for the analysis of samples. The mass spectrometric analysis, with a technical replicate for each of the 18 samples, was performed on a QExactive HF orbitrap mass spectrometer, equipped with a nanospray ion source (Thermo Fisher Scientific), coupled to the nano HPLC system. For detection, MS scans were performed in the range from m/z 400--1400 at a resolution of 60,000 (at m/z = 200). MS/MS scans were performed choosing a top 12 method; HCD fragmentation was applied at 27% normalized collision energy and analysis in the orbitrap at a resolution of 15,000 (at m/z = 200).

LC--MS shotgun data analysis {#Sec5}
----------------------------

Protein inference as well as label-free quantitative (LFQ) data analysis was performed using the open source software MaxQuant 1.3.0.5 including the Andromeda search engine and the Perseus statistical analysis package \[[@CR35], [@CR36]\], a commonly used workflow for processing and statistical assessment of shotgun proteomics data. Protein inference was achieved searching against *homo sapiens* in the SwissProt Database (version 01/2013 with 20,264 entries) allowing a mass tolerance of 5 ppm for MS spectra and 20 ppm for MS/MS spectra as well as a maximum of 2 missed cleavages. In addition, carbamidomethylation on cysteins was included as fixed modification whereas methionine oxidation as well as N-terminal protein acetylation was included as variable modifications. Furthermore, search criteria included a minimum of two peptide identifications per protein, at least one of them unique, and the FDR calculation based on q-values performed for both, peptide identification as well as protein inference, less than 0.01. Prior to statistical analysis, proteins were filtered for reversed sequences, contaminants and a minimum of three independent identifications per protein. The mass spectrometry-based proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE \[[@CR37]\] partner repository with the dataset identifier PXD007592 and <https://doi.org/10.6019/pxd007592>. Label-free quantification resulted in LFQ values for each individual protein and was used for quantitative assessment of protein regulation. For all samples the same initial protein amount of 20 µg was used and served for normalization. Using the Perseus statistical analysis package, differences of LFQ values were calculated. By applying a two-sided *t* test with *p* \< 0.05 and an FDR-based permutation correction, significantly up- and down-regulated proteins with a minimum of a twofold abundance difference (log~2~ fold change) were determined. All proteins meeting these criteria were considered in the present study. Subsequent annotation enrichment analysis was performed based on gene ontology terms biological process, cellular component and molecular function using DAVID (DAVID Bioinformatics Resources 6.7, National Institute of Allergy and Infectious Diseases) \[[@CR38], [@CR39]\]. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways according to Geiger et al. \[[@CR40]\] were visualized using Pathview package of R \[[@CR41]\]. The expression of proteins was also analyzed for significantly enriched protein sets using Gene Set Enrichment Analysis (GSEA) \[[@CR42]\]. Process using the GSEA software with the parameters set to ranking according to log fold change, minimum gene set size 15, maximum gene set size 500. To identify a potential biomarker profile, a classifier based on nearest shrunken centroids was constructed using ClaNC and R \[[@CR43]\]. Priors were chosen according to the number of samples. The performance of the classifier was tested by leaving-one-out cross validation.

Targeted LC--MS analysis {#Sec6}
------------------------

MRM method was developed based on shotgun data and using Skyline software (v.4.1) \[[@CR44]\], as described recently \[[@CR45]\]. Targeted MRM analysis was conducted on an Agilent 6490 triple quadrupole mass spectrometer coupled with a nano-Chip-LC Agilent Infinity Series HPLC1290 system. Peptides were separated by applying 19 min gradient from 8 to 30% acetonitrile. The statistical analysis of MRM data was performed with MSstats (v.2.3.5) \[[@CR46]\].

Cell culture {#Sec7}
------------

Melanoma cell cultures were established from surplus cerebral melanoma metastases after having obtained written, informed consent approved by the local IRB (EK647 and EK800). Cells were grown in RPMI (Sigma RPMI-1640, \#R0883) supplemented with 5 mM [l]{.smallcaps}-glutamine (gibco [l]{.smallcaps}-glutamine, \#25030), 1 mM sodium pyruvate (Sigma sodium pyruvate, \#S8636) and 10% FBS (PAN biotech FBS Premium heat inactivated, \#P30-1902, Aidenbach, Germany). Culture medium was changed every 2--3 days to ensure optimum conditions of growth, using aseptic techniques and a laminar flow bench. Cells were tested for mycoplasma contamination (Invivogen PlasmoTest Mycoplasma Detection Kit, \#rep-pt) prior to their use for the described techniques.

Viability assay {#Sec8}
---------------

Melanoma cells were seeded into 96-well plates in a density of 1.5 × 10^3^ cells per well. After 24 h cells were treated with Raf inhibitors Encorafenib (Selleckchem LGX818, \#S7108) or Vemurafenib (Selleckchem PLX4032, RG7204, \#S1267) and MEK inhibitor Binimetinib (Selleckchem MEK162, ARRY-162, ARRY-438162, \#S7007) in different concentrations and incubated for 72 h. Proliferation and viability of the cells was determined with a standard colorimetric assay using 7-hydroxy-3H-phenoxazin-3-one-10-oxide sodium salt (Sigma Resazurin sodium salt, \#R7017), where the bioreduction of the dye was measured at 595 nm. IC50 values were determined by nonlinear regression using the dose--response equations built into GraphPad Prism software version 5 (GraphPad Software Inc., USA).

Western blot {#Sec9}
------------

Patient derived melanoma cells were washed twice with cold PBS (gibco PBS, pH 7.4 (1X) without calcium or magnesium, \#10010) and lysed with RIPA cell lysis buffer (20 mM Tris--HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA 1% Triton-X 100, 1 mM Na~3~VO~4~, 1X protease inhibitor cocktail (Roche cOmplete ULTRA Tablets, Mini, *EASYpack*, \#05 892 970 001), 1X phosphatase inhibitor cocktail (Roche PhosSTOP *EASYpack*, \#05 906 837 001)). Total protein content was quantified using a colorimetric assay (Bio-Rad DC Protein Assay, \#5000112) according to the manufacturer's protocol with bovine serum albumin (BSA) as standard. SDS--polyacrylamide gels were hand casted with 8% separating gel and for each sample 5 µg of total protein was loaded and separated by electrophoresis for 150 min by applying 100 V (using Bio-Rad Mini-Protean Tetra Cell). Using a semi-dry transfer unit (Hoefer TE70X semi-dry blotter) proteins were blotted onto a nitrocellulose membrane (Bio-Rad Nitrocellulose membrane 0.45 µm, \#162-0115) for 90 min at 70 mA. After a blocking step for 1 h at room temperature with 5% milk (Bio-Rad nonfat dry milk Blotting-Grade Blocker, \#1706404) in TBS-T under agitation, the primary antibody (Cell Signaling E-Cadherin (24E10) Rabbit mAb, \#3195; Cell Signaling N-Cadherin (D4R1H) XP Rabbit mAb, \#13116) diluted 1:1000 in TBS-T was incubated overnight at 4 °C. After a washing step, the secondary antibody (Amersham ECL Peroxidase labelled anti-rabbit antibody, \#NA934) was diluted 1:2000 in 5% milk in TBS-T and incubated under agitation for 1 h at room temperature. After a washing step bound antibodies were detected with enhanced chemiluminescence horseradish peroxidase (Thermo Fisher Scientific SuperSignal West Pico Chemiluminescent Substrate, \#34080) in the dark room.

Immunohistochemical staining {#Sec10}
----------------------------

Cerebral melanoma metastases tissue used for immunohistochemistry was fixed in 4% formaldehyde solution and embedded in paraffin. The 4 µm sections were then deparaffinized in xylene and rehydrated. Epitope retrieval was performed in antibody specific buffers (Agilent Dako Target Retrieval Solution, pH9). Staining was performed on an immunohistochemistry stainer (Agilent Dako Autostainer Link 48) using a labeled streptavidin--biotin method visualized by AEC as chromogen (Agilent Dako REAL Detection System, Peroxidase/AEC, Rabbit/Mouse, \#K5003). The antibodies used were: CD3 (Dako Monoclonal Mouse Anti-Human CD3 Clone F7.2.38, \#M7254; 1:50); CD4 (Dako Monoclonal Mouse Anti-Human CD4 Clone 4B12, \#M7310; 1:80); CD8 (Biocare Medical CD8 \[C8/144B\], \#ACI3160A; 1:300). All slides were counterstained with hematoxylin (Agilent Dako REAL Hematoxylin, \#S2020).

Immunocytochemical staining {#Sec11}
---------------------------

Melanoma cell lines from cerebral metastases were taken out of cell culture and fixated with 7.5% formaldehyde solution. After two washing steps with PBS cells were concentrated onto glass slides using a cytospin centrifuge. Immunocytochemical staining was performed using a biotin-free detection system with horseradish peroxidase polymer and AEC chromogen (Thermo Fisher Scientific Lab Vision UltraVision LP Detection System, \#TL-015-HA). The antibodies used (Cell Signaling E-Cadherin (24E10) Rabbit mAb, \#3195; Cell Signaling N-Cadherin (D4R1H) XP Rabbit mAb, \#13116) were diluted 1:1000 in 1% BSA in PBS and incubated overnight at 4 °C. After chromogenic development all slides were counterstained with hematoxylin (Merck Papanicolaou's solution 1a Harris' hematoxylin, \#109253).

TGFβ treatment, RNA extraction and microarray data analysis {#Sec12}
-----------------------------------------------------------

The BRAFV600E mutated primary human melanoma cell line M000921 has been established from surplus material from cutaneous melanoma metastases. This cell line has been previously characterized as a proliferative-phenotype melanoma culture (by means of melanoma phenotype-switching model) and shared with multiple studies and international laboratories \[[@CR24], [@CR47]--[@CR50]\]. Expression data from a Affymetrix HG-U133 plus 2.0 oligonucleotide microarray is deposited on GEO (GSM700745). Written informed consent was approved by the local IRB (EK647 and EK800). Clinical diagnosis was confirmed by histology and immunohistochemistry. Melanoma cell culture was grown in RPMI (Sigma RPMI-1640, \#R0883) including 5 mM [l]{.smallcaps}-glutamine (gibco [l]{.smallcaps}-glutamine, \#25030), 1 mM sodium pyruvate (Sigma sodium pyruvate, \#S8636) and 10% FBS (PAN biotech FBS Premium heat inactivated, \#P30-1902, Aidenbach, Germany). M000921 melanoma cells were kept in medium containing 5 ng/ml human recombinant TGFβ (R&D Systems, \#240-B) for a period of 12 days. Medium containing fresh TGFβ protein was changed every 3 days. RNA was extracted from both untreated and TGFβ treated cell culture using TRIzol reagent (Invitrogen, USA) following manufacturer's protocol. RNA labelling, hybridization to microarray (HG-U133 plus 2.0, Affymetrix) and data were statistically analyzed as described previously \[[@CR49]\].

TCGA data {#Sec13}
---------

Gene expression and clinical information were derived from The Cancer Genome Atlas (TCGA, cutaneous melanoma dataset (n = 456)) \[[@CR51]\]. Briefly, patients were segregated according to the upper and lower quartile of gene expression and significant differences in survival rates are evaluated with the log-rank statistical test (*p* value \< 0.05). The survival curves were visualized by Kaplan--meier plots.

Results {#Sec14}
=======

Proteome profiling of cerebral melanoma metastases {#Sec15}
--------------------------------------------------

In this study we generated proteome profiling data out of cerebral melanoma metastases by shotgun proteomics. As a result, a total of 5977 proteins were detected in the tissue samples, assembled from 49,501 distinct peptides, were identified and assessed using a label-free quantification approach. Like previously described, the shotgun proteomic strategy has a unique potential to discover novel functional aspects of proteins and to determine relative abundance levels of proteins identified in different samples \[[@CR52]\]. For our comparison we assigned the samples to two groups based on patients' PFS. For further evaluation, all proteins with *p* \< 0.05 and fold change differences $\documentclass[12pt]{minimal}
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Functional discrimination of the subgroups {#Sec16}
------------------------------------------

For a functional discrimination between good and poor responder we used gene ontology (GO) annotations (Fig. [1](#Fig1){ref-type="fig"}). In order to gain a better understanding on the molecular interaction and connection of the individual candidates we mapped differentially regulated proteins to functional KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways (Fig. [2](#Fig2){ref-type="fig"}). Furthermore, Gene Set Enrichment Analysis (GSEA) \[[@CR42]\] was applied and showed very similar results (see Additional file [3](#MOESM3){ref-type="media"}: Fig. S2 for enriched pathways and Additional file [4](#MOESM4){ref-type="media"}: Table S2 for GSEA statistics). By both methods, we could show that cell adhesion molecules, calcium signaling pathway and MAPK signaling pathway proteins were overrepresented in poor responders, while complement and coagulation cascade proteins were overrepresented in good responders.Fig. 1Gene annotation enrichment analysis using the concept of GO annotations for poor responder (left column) and good responder (right column). Classification by the GO term biological process (BP) shows pathways and larger processes made up of the activities of multiple gene products, classification by the GO term cellular component (CC) shows where gene products are active and classification by the GO term molecular function (MF) shows molecular activities of gene products. Fold enrichment values for individual GO terms, count (genes involved in the term), *p* value and FDR (false discovery rate, calculated using the Benjamini--Hochberg procedure), listed next to the graph, were calculated using DAVID bioinformatics resources Fig. 2KEGG pathway visualization of the coagulation and complement cascades (**a**), cell adhesion molecules (**b**), calcium signaling pathway (**c**) and MAPK signaling pathway (**d**). Red: up-regulated in good responder; blue: down-regulated in good responder

We identified significant differentially expressed protein groups between the good (with higher PFS) and poor (with lower PFS), shown in the volcano plot (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Regulation of proteins in patients with poor and good response. The volcano plot shows the difference in the LFQ values (fold change, logarithmic scale to the base of two) on the x-axis including their corresponding *p* values (logarithmic scale) on the y-axis. Extended information on the proteins can be found in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}

Identification of proteins involved in the MAPK signaling pathway, V-type proton ATPases, calcium ion binding proteins, eukaryotic translation initiation factors, proteins involved in cell adhesion, neuronal proteins, transporter and exchanger proteins were significantly up-regulated in the poor responder group compared to the good responder group. Samples from patients who responded poorly to MAPKi treatment also showed a significant higher expression of Cadherin-2 (CDH2), also known as N-Cadherin.

Whereas patients who responded well to MAPKi showed a strong immunogenic signature, as well as proteins associated with the extracellular matrix (ECM), a subgroup of cell adhesion proteins, which are involved in immunological responses and apolipoproteins were found to be elevated amongst this subgroup. Individual proteins can be found in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}.Table 1Proteins significantly up-regulated in poor responder patients as indicated in the volcano plotAcc. Nr.Protein nameGene namelog~2~ fold change (t-test difference)*p* valuet-test significant*Eukaryotic translation initiation factors (EIFs)*Q14232Translation initiation factor eIF-2B subunit alphaEIF2B11.042.48E − 03Q14152Eukaryotic translation initiation factor 3 subunit AEIF3A1.135.71E − 03P55884Eukaryotic translation initiation factor 3 subunit BEIF3B1.573.62E − 03O00303Eukaryotic translation initiation factor 3 subunit FEIF3F1.239.41E − 03O75821Eukaryotic translation initiation factor 3 subunit GEIF3G1.594.81E − 02Q13347Eukaryotic translation initiation factor 3 subunit IEIF3I2.884.29E − 05\*Q9UBQ5Eukaryotic translation initiation factor 3 subunit KEIF3 K1.853.50E − 05Q9Y262Eukaryotic translation initiation factor 3 subunit LEIF3L1.577.30E − 03P23588Eukaryotic translation initiation factor 4BEIF4B1.691.44E − 03Q15056Eukaryotic translation initiation factor 4HEIF4H1.683.92E − 04O60841Eukaryotic translation initiation factor 5BEIF5B1.262.53E − 02*Neuronal proteins*Q8N111Cell cycle exit and neuronal differentiation protein 1CEND12.861.98E − 03P51674Neuronal membrane glycoprotein M6-aGPM6A5.305.24E − 05\*P62166Neuronal calcium sensor 1NCS13.556.65E − 05\*Q7Z3B1Neuronal growth regulator 1NEGR13.711.93E − 03Q15818Neuronal pentraxin-1NPTX13.074.79E − 03Q92823Neuronal cell adhesion moleculeNRCAM2.443.48E − 03Q9UH03Neuronal-specific septin-3SEPT33.403.68E − 04P17600Synapsin-1SYN14.682.47E − 04\*Q92777Synapsin-2SYN25.493.17E − 04\*O14994Synapsin-3SYN32.465.70E − 03*Transporter proteins*P30531Sodium- and chloride-dependent GABA transporter 1SLC6A13.448.85E − 06\*P43003Excitatory amino acid transporter 1SLC1A33.172.51E − 03P43004Excitatory amino acid transporter 2SLC1A24.985.16E − 03P43007Neutral amino acid transporter ASLC1A41.814.10E − 02P48066Sodium- and chloride-dependent GABA transporter 3SLC6A112.124.95E − 04Q15043Zinc transporter ZIP14SLC39A141.283.30E − 03Q6PML9Zinc transporter 9SLC30A91.571.36E − 02Q8N4V1Membrane magnesium transporter 1MMGT11.193.22E − 02Q8TBB6Probable cationic amino acid transporterSLC7A141.786.86E − 03Q96QE2Proton myo-inositol cotransporterSLC2A132.681.94E − 06\*Q99726Zinc transporter 3SLC30A32.032.95E − 02Q9H1V8Sodium-dependent neutral amino acid transporter SLC6A17SLC6A172.511.39E − 02Q9NS82Asc-type amino acid transporter 1SLC7A101.446.39E − 03*Exchanger proteins*P32418Sodium/calcium exchanger 1SLC8A11.664.06E − 02Q8TCU6Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 proteinPREX11.031.03E − 03Q92581Sodium/hydrogen exchanger 6SLC9A61.769.73E − 03Q9UPR5Sodium/calcium exchanger 2SLC8A24.391.18E − 03*V-type proton ATPases*Q15904V-type proton ATPase subunit S1ATP6AP11.413.12E − 02Q93050V-type proton ATPase 116 kDa subunit a isoform 1ATP6V0A12.572.75E − 04P27449V-type proton ATPase 16 kDa proteolipid subunitATP6V0C2.365.37E − 03P61421V-type proton ATPase subunit d 1ATP6V0D13.968.92E − 07\*P38606V-type proton ATPase catalytic subunit AATP6V1A1.826.37E − 05P21281V-type proton ATPase subunit B, brain isoformATP6V1B21.622.37E − 04P21283V-type proton ATPase subunit C 1ATP6V1C11.515.27E − 05Q9Y5K8V-type proton ATPase subunit DATP6V1D2.195.15E − 04P36543V-type proton ATPase subunit E 1ATP6V1E11.276.60E − 04Q16864V-type proton ATPase subunit FATP6V1F3.125.47E − 07\*O75348V-type proton ATPase subunit G 1ATP6V1G12.395.16E − 04O95670V-type proton ATPase subunit G 2ATP6V1G21.404.11E − 04Q9UI12V-type proton ATPase subunit HATP6V1H2.754.83E − 04*MAP-kinases*P28482Mitogen-activated protein kinase 1MAPK11.786.70E − 04P53779Mitogen-activated protein kinase 10MAPK102.271.27E − 03P27361Mitogen-activated protein kinase 3MAPK31.791.39E − 03Q9UPT6C-Jun-amino-terminal kinase-interacting protein 3MAPK8IP32.211.83E − 03*Cell adhesion proteins*O00533Neural cell adhesion molecule L1-like proteinCHL11.593.85E − 02O15394Neural cell adhesion molecule 2NCAM22.561.84E − 02P13591Neural cell adhesion molecule 1NCAM13.721.12E − 04\*P32004Neural cell adhesion molecule L1L1CAM4.271.91E − 06\*Q14982Opioid-binding protein/cell adhesion moleculeOPCML4.537.99E − 04\*Q14CZ8Hepatocyte cell adhesion moleculeHEPACAM2.491.23E − 02Q8N3J6Cell adhesion molecule 2CADM24.321.24E − 03Q8NFZ8Cell adhesion molecule 4CADM41.742.53E − 02Q92823Neuronal cell adhesion moleculeNRCAM2.443.48E − 03*Calcium-ion binding proteins*P62158CalmodulinCALM11.369.22E − 06Q14012Calcium/calmodulin-dependent protein kinase type 1CAMK12.174.56E − 04Q9UQM7Calcium/calmodulin-dependent protein kinase type II subunit alphaCAMK2A3.005.85E − 04Q13554Calcium/calmodulin-dependent protein kinase type II subunit betaCAMK2B3.982.08E − 03Q13555Calcium/calmodulin-dependent protein kinase type II subunit gammaCAMK2G2.775.24E − 03Q16566Calcium/calmodulin-dependent protein kinase type IVCAMK41.981.25E − 02Q8N5S9Calcium/calmodulin-dependent protein kinase kinase 1CAMKK12.138.09E − 03Q96RR4Calcium/calmodulin-dependent protein kinase kinase 2CAMKK22.038.67E − 03Q9P1Y5Calmodulin-regulated spectrin-associated protein 3CAMSAP32.358.13E − 03P54750Calcium/calmodulin-dependent 3,5-cyclic nucleotide phosphodiesterase 1APDE1A1.975.00E − 03Q01064Calcium/calmodulin-dependent 3,5-cyclic nucleotide phosphodiesterase 1BPDE1B2.541.25E − 02*EMT*P19022Cadherin-2CDH22.531.02E − 03The table shows UniProt accession number (Acc. Nr.), protein name, gene name, t-test difference between LFQ values of poor and good responding patients (fold change, logarithmic scale to the base of two) with corresponding *p* values and t-test significance (rows with a t-test result above s0 = 0.5 and FDR 0.01 are reported as significant) Table 2Proteins significantly up-regulated in good responder patients as indicated in the volcano plotAcc. Nr.Protein nameGene namelog~2~ fold change (t-test difference)*p* valuet-test significant*Immune response related proteins*P05164MyeloperoxidaseMPO4.531.69E − 05\*P01909HLA class II histocompatibility antigen, DQ alpha 1 chainHLA-DQA11.431.01E − 03P04233HLA class II histocompatibility antigen gamma chainCD741.747.47E − 03P20039HLA class II histocompatibility antigen, DRB1-11 beta chainHLA-DRB12.992.46E − 03Q95365HLA class I histocompatibility antigen, B-38 alpha chainHLA-B1.843.64E − 03Q5Y7A7HLA class II histocompatibility antigen, DRB1-13 beta chainHLA-DRB11.381.70E − 03P01594Ig kappa chain V-I region AU1.077.46E − 03P01609Ig kappa chain V-I region Scw1.582.02E − 03P01613Ig kappa chain V-I region Ni1.861.68E − 02P01617Ig kappa chain V-II region TEW1.614.60E − 03P01623Ig kappa chain V-III region WOL1.891.87E − 03P01777Ig heavy chain V-III region TEI1.781.97E − 03P01767Ig heavy chain V-III region BUT1.463.39E − 02P01779Ig heavy chain V-III region TUR2.249.82E − 04P01834Ig kappa chain C regionIGKC1.564.17E − 03P01857Ig gamma-1 chain C regionIGHG11.409.49E − 03P01860Ig gamma-3 chain C regionIGHG31.421.01E − 02P01871Ig mu chain C regionIGHM2.247.25E − 03P01876Ig alpha-1 chain C regionIGHA11.125.26E − 02P01880Ig delta chain C regionIGHD1.364.04E − 02*Apolipoproteins*O14791Apolipoprotein L1APOL11.821.43E − 03P02647Apolipoprotein A-IAPOA11.942.86E − 04P04114Apolipoprotein B-100APOB3.551.17E − 03P06727Apolipoprotein A-IVAPOA45.062.61E − 06\**Cell adhesion (in immune response)*P16284Platelet endothelial cell adhesion moleculePECAM11.485.04E − 02P31997Carcinoembryonic antigen-related cell adhesion molecule 8CEACAM81.863.08E − 03P40199Carcinoembryonic antigen-related cell adhesion molecule 6CEACAM61.163.99E − 02*Extracellular matrix (ECM) components*P02452Collagen alpha-1(I) chainCOL1A13.672.18E − 02P02751FibronectinFN12.614.26E − 03P08123Collagen alpha-2(I) chainCOL1A23.241.25E − 02P25067Collagen alpha-2(VIII) chainCOL8A21.299.84E − 03P39059Collagen alpha-1(XV) chainCOL15A11.484.46E − 02Q05707Collagen alpha-1(XIV) chainCOL14A12.535.55E − 02Q96P44Collagen alpha-1(XXI) chainCOL21A11.783.42E − 02The table shows UniProt accession number (Acc. Nr.), protein name, gene name, t-test difference between LFQ values of poor and good responding patients (fold change, logarithmic scale to the base of two) with corresponding *p* values and t-test significance (rows with a t-test result above s0 = 0.5 and FDR 0.01 are reported as significant)

Identification of discriminative proteins {#Sec17}
-----------------------------------------

To generalize our proteomic findings and enable the translation of the results towards clinical application, we constructed a classifier based on nearest shrunken centroids to identify a potential biomarker profile. We were able to identify 9 proteins that are needed to discriminate between good and poor responders shown in Table [3](#Tab3){ref-type="table"} and illustrated in Fig. [4](#Fig4){ref-type="fig"}.Table 3Classification to nearest shrunken centroids for identification of the most class-discriminating proteinsAcc. Nr.Protein nameGene namelog~2~ fold change (t-test difference)\
upregulated in poor responder*p* valuet-test significantFunctional roleP21266Glutathione S-transferase Mu 3GSTM32.687.13E − 07\*Uptake and detoxification of endogenous compounds and xenobiotics at the blood brain barrier \[[@CR80]\]; many anticancer drugs are substrates for GST and, therefore, overexpression of GST is responsible for resistance to anti-cancer drugs in tumor cell lines \[[@CR81]\]P61962DDB1- and CUL4-associated factor 7DCAF72.061.11E − 07\*Substrate receptor for a ubiquitin-protein ligase complex; involved in the pathway protein ubiquitination; involved in normal and disease skin development \[[@CR82]\]; has been shown to function as a scaffold protein for protein complexes involved in kinase signalling \[[@CR83]\]P62937Peptidyl-prolyl cis--trans isomerase APPIA0.754.98E − 07Upregulated in resistant human breast cancer cell line (vs. sensitive cell line) \[[@CR84]\]; PPIases accelerate the folding of proteins; catalyzes the cis--trans isomerization of proline imidic peptide bonds in oligopeptides \[[@CR85]\]Q16864V-type proton ATPase subunit FATP6V1F3.125.47E − 07\*V-ATPases are responsible for acidifying intracellular compartments \[[@CR86]\]; an acidic environment leads to inactivation of T cells \[[@CR56], [@CR57]\]; supports the hypothesis that resistance is caused by the tumor inactivating immune cellsQ6FI81AnamorsinCIAPIN12.462.38E − 05Anti-apoptotic effects in the cell; involved in negative control of cell death upon cytokine withdrawal \[[@CR87]\]; may participate in breast cancer multi drug resistance (MDR) by regulating MDR1 and P53 expression, changing cell cycle and enhancing the anti-apoptotic capability of cells \[[@CR88]\]Q6UWP2Dehydrogenase/reductase SDR family member 11DHRS112.101.64E − 07\*Involved in estrogen biosynthesis, which is part of steroid biosynthesis \[[@CR89]\]; proposed role in sex hormone, neurosteroid, androgen, estrogen and bile acid metabolism; mRNA highly expressed in testis, small intestine, colon, kidney and cancer cell lines \[[@CR90]\]Q7Z7E8Ubiquitin-conjugating enzyme E2 Q1UBE2Q11.803.14E − 05Catalyzes the covalent attachment of ubiquitin to other proteins \[[@CR91]\]; may function as an oncogene that induces proliferation of cancer cells, and could be a novel diagnostic tool and a potential therapeutic target for colorectal cancer (CRC) \[[@CR92]\]Q8IVD9NudC domain-containing protein 3NUDCD32.422.78E − 05Interacts selectively and non-covalently with an unfolded protein; functions to maintain the stability of dynein intermediate chain \[[@CR93]\]; depletion of this gene product results in aggregation and degradation of dynein intermediate chain, mislocalization of the dynein complex from kinetochores, spindle microtubules, and spindle poles, and loss of gamma-tubulin from spindle poles \[[@CR94]\]Q8N4Q0Prostaglandin reductase 3ZADH22.482.44E − 06\*Negatively modulates adipogenesis through regulation of PPARγ activity \[[@CR95]\]; knockdown of prostaglandin reductase 1 (PTGR1) suppresses prostate cancer cell proliferation by inducing cell cycle arrest and apoptosis \[[@CR96]\]The table shows UniProt accession number (Acc. Nr.), protein name, gene name, t-test difference between LFQ values of poor and good responding patients (fold change, logarithmic scale to the base of two) with corresponding *p* values and t-test significance (rows with a t-test result above s0 = 0.5 and FDR 0.01 are reported as significant) Fig. 4Protein panel displays differences between poor and good responders. For each of the 9 most class-discriminating proteins (listed in Table [3](#Tab3){ref-type="table"}), label-free quantification (LFQ) intensities in a logarithmic scale to the basis 2 are indicated. LFQ intensities for proteins not detected in a replicate were replaced by 15

EMT feature as a major classifier between good and poor prognosis validated in primary melanoma cell cultures {#Sec18}
-------------------------------------------------------------------------------------------------------------

With the LC--MS shotgun approach we could show that samples from patients who responded poorly to MAPKi treatment showed a significantly higher expression of Cadherin-2 (CDH2), also known as N-Cadherin. For independent validation, we performed immunocytochemistry on primary melanoma cell cultures derived from cerebral melanoma metastases and Western blot on the lysates of these cells with E- and N-cadherin antibodies. The melanoma cells are classified as either sensitive (n = 3) or resistant (n = 2) based on the IC50 values for the BRAF/MEK inhibitors as determined by a viability assay. By these experiments we could show that the sensitive cells are E-cadherin positive, whereas the resistant cells were N-cadherin positive. This data strongly suggests EMT as a major classifier between good and poor prognosis (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Primary melanoma cell cultures derived from cerebral metastases. Stratification of the samples by proliferation and viability assay and calculation of the IC50 for BRAF/MEK inhibitors (**a**). Sensitive cells show E-cadherin positivity and N-cadherin negativity in immunocytochemistry (**b**) and Western blot (**c**), whereas resistant cells show E-cadherin negativity and N-cadherin positivity

Validation of discriminative signature by CPL/MUW proteome database {#Sec19}
-------------------------------------------------------------------

To further assess the discriminative signature (Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) on protein level we tested the candidates using CPL/MUW proteome database \[[@CR30]\], including 255 cell cultures, cell states and tissue, leading to a high protein similarity (57.14%) to the resistant melanoma cell line TMFI \[[@CR30], [@CR53]\]. In addition, we found one protein of our signature exclusively in TMFI, supporting our observation that this set of proteins is apparently characteristic for resistance (Additional file [5](#MOESM5){ref-type="media"}: Fig. S3).

Validation and quantification of discriminative proteins by a targeted LC--MS analysis {#Sec20}
--------------------------------------------------------------------------------------

Furthermore, we validated and quantified the discriminative protein signature (Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}) with a targeted MS approach. We were able to validate our previous findings by the shotgun MS screen demonstrating significant protein expression between the groups of good and poor responding patients (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Intensities from the targeted MS approach for 8 of the 9 proteins from the discriminative signature listed in Table [3](#Tab3){ref-type="table"}. Statistics for this plot were done in MSstats (\**p* value \< 0.05, \*\**p* value \< 0.01, \*\*\**p* value \< 0.001)

EMT-like signature induced by TGFβ can be correlated to the signature of poor responder {#Sec21}
---------------------------------------------------------------------------------------

TGFβ-induced epithelial-to-mesenchymal-like transition (EMT-like) has been described in melanoma recently \[[@CR25]\] and is characterized by melanoma cells switching from a proliferative phenotype to an invasive phenotype which is accompanied by induced drug-resistance to BRAF and MEK inhibitor treatment \[[@CR24], [@CR54]\]. Here we have correlated genes upregulated by TGFβ (EMT genes) to proteins up-regulated in brain metastasis of melanoma patients treated with BRAF and MEK inhibitors (see Fig. [7](#Fig7){ref-type="fig"} for functional annotation categories (DAVID Bioinformatics Resources 6.7, National Institute of Allergy and Infectious Diseases) and Additional file 6: Table 3 for full list of overlapping data between TGFβ induced signature in microarray data and shotgun proteomics data in cerebral melanoma metastases). Correlation of factors regulated in TGFβ induced EMT with the proteome signature of the patients that showed poor response was significant.Fig. 7Functional annotation categories calculated in DAVID (DAVID Bioinformatics Resources 6.7, National Institute of Allergy and Infectious Diseases) of correlating genes upregulated by TGFβ (EMT genes) to proteins up-regulated in brain metastasis of melanoma patients treated with BRAF and MEK inhibitors (see Additional file [4](#MOESM4){ref-type="media"}: Table S2 for full list of overlapping data between TGFβ induced signature in Microarray data and shotgun proteomics data in cerebral melanoma metastases). Fold enrichment values, count (genes involved in the term), *p* value and FDR (false discovery rate, calculated using the Benjamini--Hochberg procedure), listed next to the graph, were calculated using DAVID bioinformatics resources

Correlation of the resistance signature to patient survival {#Sec22}
-----------------------------------------------------------

To demonstrate clinical relevance of the protein signature we researched the melanoma dataset (n = 456) of The Cancer Genome Atlas (TCGA) \[[@CR51]\] and were able to show that three candidates, DDB1- and CUL4-associated factor 7, Ubiquitin-conjugating enzyme E2 Q1 and Anamorsin, out of the 9 discriminative proteins correlate with patients' survival (Fig. [8](#Fig8){ref-type="fig"}).Fig. 8Kaplan-meier plots visualizing the survival of patients for DDB1- and CUL4-associated factor 7 (**a**), Ubiquitin-conjugating enzyme E2 Q1 (**b**) and Anamorsin (**c**) based on The Cancer Genome Atlas dataset (TCGA, cutaneous melanoma dataset (n = 456))

Increased immune cell presence in the cerebral metastases of good responder {#Sec23}
---------------------------------------------------------------------------

The proteome signature of good responders was defined also by the up-regulation of immunogenic markers which we confirmed by immunohistochemical staining on the different T cell populations (CD3, CD4, CD8) on the FFPE cohort of clinical samples. These samples were classified as either good responder (n = 7) or poor responder (n = 15) based on PFS. The stained slides were evaluated by a dermatopathologist. Here we were able to demonstrate that poor response is characterized by less immune cell infiltrate in melanoma brain metastases, confirming our observation of higher immunological potential in the good responder (Fig. [9](#Fig9){ref-type="fig"}).Fig. 9Immunohistochemistry of FFPE cerebral melanoma metastases cohort (n = 22). Evaluation of good responders (n = 7) versus poor responders (n = 15) shows significant different expression of he T cell marker CD3 (orange; *p* value = 0.002), CD4 (green; *p* value = 0.025) and CD8 (blue; *p* value = 0.007) visualized in the scatter plot (**a**) and by examples of the staining results (**b**)

Discussion {#Sec24}
==========

In this study design we used a five-step approach from MS proteome analysis up to clinical validation of patient samples in order to describe two distinct protein expression signatures defining treatment outcome to MAPK inhibition of patients with metastatic melanoma to the brain. Starting with shotgun MS to identify differentially expressed proteins between a set of good and poor responders with brain metastasis to targeted therapy. Next a variety of pathway analysis tools, GO terms, KEGG pathways, and GSEA, to define a set of biological and signaling pathways to distinguish between the good and poor responders. In step three we applied the nearest shrunken centroid classifier method and were able to define a 9 protein signature. Discriminative proteins were validated in step four by CPL/MUW proteome database and an EMT signature in vitro in melanoma cells derived from brain metastasis resistant to MAPK inhibition. Our next step was further validation and also quantification over a targeted MS approach. This was followed by a functional validation of the EMT signature. Finally, in the last step we also showed clinical validation by correlating survival of patients with the resistant signature and performed immunohistochemistry on cerebral melanoma metastases. Employing proteomic analysis, we confirmed known extra-cerebral resistance mechanisms in cerebral metastases and further uncovered possible brain specific mechanisms of drug efflux, which might serve as treatment targets or as predictive markers for these kinds of metastases.

After our initial screen using shotgun LC--MS, we investigated pathways differing most apparently between good and poor responders. The MAPK signaling pathway was most reassuring since it represents one of the main resistance mechanisms known in melanoma \[[@CR55]\].

We then searched for protein candidates, which played a role in these pathways and performed literature search in order to investigate whether these markers play a role in resistance mechanisms (Fig. [3](#Fig3){ref-type="fig"}).

V-type proteins, a group of proton ATPases, are significantly up-regulated in poor responders. V-type proton ATPases transport hydrogen ions (H+) across membranes, which may cause an acidic environment and thus lead to inactivation of T cells \[[@CR56], [@CR57]\]. This might support the hypothesis that resistance is supported by inactivating immune cells. V-type proteins might also be involved in drug efflux; their role in acidifying the ECM and thus maintaining multi-drug-resistance (MDR) properties has already been shown \[[@CR58]\].

Eukaryotic translation initiation factors (EIFs) are pivotal in cancer progression and involved in different hallmarks of cancer \[[@CR59], [@CR60]\]. Complexes of this group of proteins have been shown to function as a nexus of resistance to anti-BRAF and anti-MEK cancer therapies \[[@CR61]\] and were also found up-regulated in the samples of patients with poor response to MAPKi treatment.

The overrepresentation of a large group of neuronal proteins (Table [1](#Tab1){ref-type="table"}) matches with their suspected role in cell migration and metastasis. Here, where the movement of cells is controlled, similar processes as in axon guiding are happening. A group of secreted axon guidance molecules, involved in neuronal development, has already been discussed and proven to be overexpressed in various carcinomas, as well as melanoma. It was also shown that the expression was correlated with advanced stage and grade of cancer \[[@CR62]\]. Since the involvement of neuronal axon guiding factors in metastasis has been demonstrated by previous studies \[[@CR63]\], it can be hypothesized, that a reinforced neuronal profile may be a sign of increased migration and resistance to MAPKi of brain metastases, making neuronal proteins a potential target for future therapeutic approaches.

Demonstrated by the heterogeneity in therapeutic resistance, the plasticity of melanoma cells might allow the tumor to adapt to biological processes, for example by EMT-like mechanisms. There are various specific molecular events associated with EMT, such as increased production of ECM components, activation of transcription factors and reorganization and expression of cytoskeletal proteins \[[@CR21], [@CR28]\]. EMT is also associated with induction of resistance and metastasis \[[@CR26], [@CR28], [@CR29]\]. Especially, the down-regulation of E-cadherin is balanced by the increased expression of mesenchymal neural cadherin (N-cadherin). This, so called cadherin switch, alters cell adhesion \[[@CR26], [@CR27]\] and is considered to be a fundamental event in EMT, leading to a loss of cell--cell contact, increased invasive properties and typical morphological changes \[[@CR21], [@CR28], [@CR29]\]. EMT is associated with an induction of the mesenchymal marker N-cadherin or Cadherin-2 (CDH2), which we have shown to be significantly up-regulated in poor responders. The biological reason behind the changes to a mesenchymal phenotype is the increased capability to detach from the epithelial layer and to gain the ability for migration \[[@CR28]\].

The concept of phenotype switching, first described in melanoma by Hoek et al. \[[@CR19], [@CR20]\], characterizes two transcriptional distinct melanoma cell populations, a proliferative and an invasive type. The phenotype-switching model accounts for disease progression and tumor heterogeneity, as well as aspects of resistance \[[@CR22]\]. Melanoma cells are able to switch back and forth between these two phenotypes \[[@CR21]\]. Also, melanoma cells have shown to change their phenotype from proliferative to invasive state in response to targeted therapy with BRAFi and MEKi, which is associated with drug resistance. Furthermore, proliferative melanoma cells have been shown to be more responsive to MAPK pathway inhibition than invasive phenotype cells, independently of their mutation status \[[@CR23], [@CR24]\]. The major role in phenotype switching and the transition from a proliferative to an invasive cell type and ultimately leading to metastasis is related to EMT-like mechanisms \[[@CR25]\]. Identifying critical switches in EMT processes and finding a way to block these, might serve as a strategy to prevent metastasis and to decrease therapeutic resistance. The presently characterized mechanisms might thus not only provide insight into mechanisms of resistance but may also increase the understanding of the metastasis processes. In this pilot study, we were able to detect EMT features, as well as an increase of proteins involved in calcium ion binding and cell adhesion in line with previous published data \[[@CR53]\]. Interaction with the ECM is also important for metastasis, since cells need to be able to adhere. A recently published study also exhibited a higher capability of cell adherence demonstrating that Vemurafenib resistant cells undergoing EMT have an increased ability to interact with ECM proteins \[[@CR64]\].

Possible potential lies in the identified groups of exchanger and transporter proteins (Table [1](#Tab1){ref-type="table"}), which we detected an over-representation in the poor responder patient group. There are candidates among the transporter proteins, which are not only involved in leukocyte migration but also in many transport processes. It can therefore be hypothesized that these transport activities also take place in drug efflux, leading or contributing to therapy resistance. Enhanced drug efflux membrane transporters has already been described in chemoresistance \[[@CR65]\]. Na+/H+ exchangers or antiporters have been associated with cancer metastasis and invasion \[[@CR66]--[@CR69]\], making them valuable for future drug development \[[@CR70]\].

Patients who responded well to MAPKi treatment revealed a huge number of significantly up-regulated immune response related proteins such as myeloperoxidase (MPO), HLA proteins and immunoglobulin chains. Although these patients were not treated with immunotherapy, the immune system is always involved in cancer defense. This leads to the presumption that in patients who showed good response to therapy, melanoma is better recognizable for the immune system via these up-regulated receptors and fragments. It also has recently been shown that many subtypes of HLA molecules are down-regulated during MAPKi resistance \[[@CR71]\], supporting the good response of patients with up-regulated HLA proteins. MPO is a peroxidase enzyme expressed in professional phagocytic cells, most abundantly in neutrophils. It is involved in cellular homeostasis and of particular interest because of its important role in the initiation and progression of acute and chronic inflammatory diseases \[[@CR72]\]. Although in some cases of neoplastic malignancies there is research pointing out the actively tumor promoting function of immune inflammatory cells \[[@CR60]\], there are also mechanisms known by which adaptive immune cells modulate cancer for example by cytokine-mediated lysis of tumor cells \[[@CR73]\]. ECM structural constituents, as well as proteins involved in cell adhesion were significantly up-regulated amongst patients who showed a good response to therapy. Compared to poor responders, in this case the cell adhesion molecules are involved in immune response, leukocyte migration and ECM organization. This accounts for the activation of the immune system and may be due to the organism attacking the metastases. Apolipoproteins might be another interesting group for further investigation. In patients with good treatment response they were significantly up-regulated and have already been described as a probable prognostic factor and can be predictive for survival \[[@CR74]\].

Finally, we wanted to be able to differentiate between good and poor responding patients and translate our data towards clinical application. To identify a potential biomarker profile, we constructed a classifier based on nearest shrunken centroids. We identified 9 proteins that are necessary to discriminate between good and poor responding patients, namely Glutathione S-transferase Mu 3, DDB1- and CUL4-associated factor 7, Peptidyl-prolyl cis--trans isomerase A, Anamorsin, Dehydrogenase/reductase SDR family member 11, Ubiquitin-conjugating enzyme E2 Q1, NudC domain-containing protein 3, Prostaglandin reductase 3 and V-type proton ATPase subunit F (Fig. [4](#Fig4){ref-type="fig"}). Literature research demonstrated that these candidates are involved in resistance or tumor progression and exert novelty in the field of melanoma resistance (Table [3](#Tab3){ref-type="table"}).

With the targeted approach we were successfully able to validate 8 out of the 9 proteins.

We also made use of the TCGA database, which provides clinical information and gene expression of 456 melanoma samples. Here we were able to correlate DDB1- and CUL4-associated factor 7 (DCAF7), Ubiquitin-conjugating enzyme E2 Q1 (UBE2Q1) and Anamorsin (CIAPIN1) also on gene expression level with poor survival, demonstrating clinical relevance of the protein signature.

As previously described EMT plays a crucial role in metastasis. By inducing EMT in a cell culture melanoma model with previous sensitivity, we detected the typical signature also identified in the poor responding patients. This fortifies EMT as a major classifier between good and poor prognosis. We could validate the observation that EMT is an important process in resistance in brain metastases of melanoma by staining on the main factors involved in EMT (E- and N-cadherin) by immunocytochemistry and Western blotting.

High amounts of tumor-infiltrating lymphocytes (TILs), high ratios of PD-1+/CD8+ cells and high levels of PD-L1 were shown to be negatively correlated with brain metastases size, although there was no significant association of patient survival with TILs \[[@CR75]\]. Another study showed that T-cell specific genes such as CD3 and CD8 are expressed at higher levels in patients with a prolonged overall survival \[[@CR76]\]. Meaning any molecule associated with the presence of T cells implies a better outcome, which is consistent with the published literature about the association of TILs with good prognosis. Concerning TILs, CD3+ and CD8+ T cells may be the most important effector population during regression of melanoma metastasis \[[@CR77]\]. T cell infiltrated melanomas, especially those with high CD8+ cells, are more likely to be associated with PD-L1 expression in tumor cells, an increased prognosis and increased time to develop brain metastasis \[[@CR78]\]. With our FFPE cohort we were able to demonstrate that poor response is characterized by a lower infiltrate of immune cells in melanoma brain metastases confirming our observation of the over-representation of immunogenic marker in the good responder. This is in line with recent literature and gives new insights into MAPKi resistance and brain metastases. This leads us to the assumption that also MAPKi resistant patients could benefit from immunotherapy-induced activation of their immune system, since we see higher immune infiltration in tumors of patients that responded well to therapy.

Conclusions {#Sec25}
===========

Drug resistance mechanisms are content of latest research. Calcium ion binding proteins, EIFs, EMT, lysosomal pathway and others have already been identified by previous proteome analyses as main features associated with resistance. With our tissue proteomic approach, we were able to detect similar resistance mechanisms in cerebral metastases, indicating resemblance to visceral metastases. The cerebral metastases of poorly responding patients expressed transporter and exchanger proteins in a higher amount, which might, especially in the brain, be responsible for drug efflux and thus contribute to therapy resistance. With patients who showed good response to therapy the immunogenic signature indicates a better response to targeted therapy combined with immunotherapy. This suggests that patients with a poor response to MAPKi might also benefit from activating their immune system. Further studies analyzing the function of these targets are warranted. Evaluation of new treatment options in vitro is necessary to verify possible candidates. Additional studies with increased sample size will also give more profound insights into the pathomechanisms of MAPKi resistance. Intensive research is demanded for the detection of promising therapeutics and to understand resistance mechanisms. Primary tumors collected today are from huge relevance, not only for research but also for the patient. The availability of adequate sample material for future studies will determine the validity of the gained evidence. By initiating appropriate biobank approaches, future scientific endeavors to develop novel therapies or stratification of patients for better treatment can be ensured \[[@CR79]\].

Additional files
================

 {#Sec26}

**Additional file 1: Figure S1.** Study outline shows the experimental design of the study. **Additional file 2: Table S1.** Clinical table with age, gender, treatment, response distribution, PFS, mutational status, all number of samples, IC50 of the cell systems and the applied methods. **Additional file 3: Figure S2.** Complement and coagulation cascades (A) are enriched in good responder. Cell adhesion molecules (B), calcium signaling pathway (C) and MAPK signaling pathway (D) are highly enriched and up-regulated in poor responder, as visualized by GSEA. **Additional file 4: Table S2.** Statistical output for GSEA (gene set enrichment analysis). Nominal p-value, false discovery rate (FDR) and familywise-error rate (FWER) are given for the for significantly enriched protein sets. **Additional file 5: Figure S3.** Correlation of proteins (P62937, P61962, Q6FI81, P21266) identified by nearest shrunken centroid and CPL/MUW proteome database, including 255 cell cultures, cell states and tissue, leading to a high protein similarity to the resistant melanoma cell line TMFI. **Additional file 6: Table S3.** Genes upregulated in melanoma cells by TGFβ signaling correlating with proteins that were also found to be upregulated in the cerebral melanoma metastases by proteomics.
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